Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

• Published in: JAMA : the journal of the American Medical Association Vol. 311; no. 19; pp. 1998 - 2006
• Main Authors: Kris, Mark G, Johnson, Bruce E, Berry, Lynne D, Kwiatkowski, David J, Iafrate, A. John, Wistuba, Ignacio I, Varella-Garcia, Marileila, Franklin, Wilbur A, Aronson, Samuel L, Su, Pei-Fang, Shyr, Yu, Camidge, D. Ross, Sequist, Lecia V, Glisson, Bonnie S, Khuri, Fadlo R, Garon, Edward B, Pao, William, Rudin, Charles, Schiller, Joan, Haura, Eric B, Socinski, Mark, Shirai, Keisuke, Chen, Heidi, Giaccone, Giuseppe, Ladanyi, Marc, Kugler, Kelly, Minna, John D, Bunn, Paul A
• Format: Journal Article
• Language: English
• Published: Chicago, IL American Medical Association 21.05.2014
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - genetics; Adenocarcinoma of Lung; Aged; Bioassays; Biological and medical sciences; Clinical outcomes; Female; General aspects; Genomics; Genotype; Humans; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Male; Medical sciences; Middle Aged; Molecular Targeted Therapy; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Multiplex Polymerase Chain Reaction; Oncology; Pharmaceuticals; Pneumology; Proto-Oncogenes; Sequence Analysis, DNA - methods; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Analysis; Tumors; Tumors of the respiratory system and mediastinum; Assay; Medicine; Lung disease; Carcinogen; Respiratory disease; Lung cancer; Targeted drug; Bronchus disease; Malignant tumor; Carcinogenesis; Cancer

IMPORTANCE Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung adenocarcinomas. The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in...